Nasal vaccine platform Vivaldi’s Delta NS1 nasal spray platform and self-adjuvanting approach present an opportunity to cross-sell to infectious disease programs, offering a rapid-onset mucosal immunity solution that complements systemic vaccines.

Universal flu focus DeltaFLU universal influenza vaccine in Phase 2 and upcoming Delta-19 trials position Vivaldi as a partner for collaborations or contract development for broad-coverage respiratory vaccines, appealing to institutions seeking pan-flu strategies.

Pandemic preparedness Strong emphasis on epidemic and pandemic viral respiratory protection aligns with public health and government programs, suggesting sales potential with governments, NGOs, and large healthcare networks seeking resilient vaccines.

Clinical and translational potential Recent and ongoing clinical development combined with demonstrated data presentations at major conferences creates openings for sponsored studies, technical collaborations, and ancillary services with CROs and biotech partners.

Strategic funding signals Recent grants and private investment signaling momentum, plus a lean team footprint, indicate appetite for strategic partnerships, licensing, or co-development deals with larger contract manufacturers and biotech players.